Sentence examples for multiple targeted agents from inspiring English sources

The recent development of multiple targeted agents for metastatic renal cell carcinoma (mRCC) has changed the treatment paradigm; hence the benefit and optimal timing of cytoreductive nephrectomy is being reevaluated.

The need to test multiple new targeted agents both alone and in combination with other targeted therapies, as well as classic cytotoxic agents, demands the development of novel therapeutic platforms (particularly Master Protocols) capable of efficiently and effectively testing multiple targeted agents or targeted therapeutic strategies in relatively small patient subpopulations.

These data have important implications for treatment strategies where use of multiple targeted agents is being considered and highlight the significance of the K-Ras and Stat pathways for tumorigenesis and tumor maintenance.

Recent clarification of the molecular mechanisms of RCC has permitted tremendous progress in the development and approval of multiple targeted agents for the treatment of advanced RCC.

Furthermore, the study underscores the relevance of empirically testing the sensitivity of mutant tumors to multiple targeted agents as specific genetic alterations may dictate the tumor response to targeted therapy.

ErbB3-mediated signaling was identified as a potent mechanism of resistance to multiple targeted agents, and combining the ErbB3 inhibitor MM-111 with ErbB2 inhibitors was found to induce synergistic tumor regression.

Complex tumour types may be more susceptible to the use of multiple-targeted agents or to drugs that target generic, fundamental tumour processes such as angiogenesis, apoptosis and cellular proliferation.

This may be particularly relevant to efforts to improve trial efficiency in order to test multiple targeted new agents in combination.

As we have entered the era of multiple antiangiogenic targeted agents for the treatment of mRCC more cases of RLPS are anticipated.

The clinical development of treatment protocols incorporating multiple molecular targeted agents is problematic, because the optimum combination would depend on the specific pattern abnormalities in a particular cancer patient.

Detection of preexisting therapy-resistant mutations in sub-population within the primary tumor will enable the treatment of patients with multiple targeting agents at the time of initial targeted therapy.